What happened
The Office of the United States Trade Representative will hold a public hearing on September 22, 2026, local time, according to a report from Cailianshe.
The hearing concerns the Section 301 investigation into Germany's pharmaceutical policies.
Why it matters
A public hearing signals that the investigation has reached a stage where stakeholders can present views on the record, which is typically a step before any determination or action.
Because Section 301 probes can lead to trade measures, the proceeding puts German pharmaceutical policy squarely on the U.S. trade agenda, though the source material does not indicate what outcome, if any, is expected.
Key facts
The U.S. Trade Representative's Office will hold a public hearing on September 22, 2026, local time.
The hearing will discuss the Section 301 investigation into German pharmaceutical policies.
The report comes from Cailianshe.
What to watch next
Whether the hearing produces any indication of the investigation's direction or timeline.
Any subsequent statements from the U.S. Trade Representative's Office or German officials following the hearing.
